Facebook
Twitter
LinkedIn
Forward
According to the Patient: Alopecia Areata in Adolescence
The management of AA in adolescents presents various challenges to dermatology professionals, including identification of AA, limited effective treatment options, and high disease burden. Because hair loss has a significant physical and psychological impact on a child’s development, early diagnosis and treatment are essential. Currently there is only one systemic therapy approved for adolescents; however, there are additional therapies on the horizon with promising data. As new therapies continue to emerge and become available, clinicians should become familiar with the clinical efficacy and safety data for current and emerging therapies to inform treatment selection and capitalize on the treatment benefits.
This educational activity, originally presented by Britt Craiglow, MD, and Brett King, MD, PhD live at the 2024 South Beach Symposium and Masters of Pediatric Dermatology conferences, focuses on the pathophysiology and clinical presentations of AA, current and emerging therapies, and disease management strategies for adolescents with AA.
Target Audience
This activity is designed for an audience of U.S. based dermatologists, pediatric dermatologists, nurses, advanced practice providers who treat alopecia areata.
Learning Objectives
Upon completion of the educational activity, participants should be better able to:
- Describe the pathophysiology and variations in clinical presentations of AA in adolescent patients.
- Evaluate clinical data for current and emerging therapies for adolescents with AA.
- Develop disease management strategies to address the comorbidities, psychosocial effects, QoL, and disease burden in adolescents with AA.
- Recorded symposium
 |  |
Brett King, MD, PhD Associate Professor of Dermatology Yale School of Medicine New Haven, CT | Brittany Craiglow, MD Adjunct Associate Professor Yale School of Medicine New Haven, CT |
This activity is provided by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm.
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
1 ANCC contact hours.
Physician Assistant
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credit. Approval is valid until May 15, 2025. PAs should only claim credit commensurate with the extent of their participation.
Commercial Support
This activity is supported by an educational grant from Pfizer.
Disclosure
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
DISCLOSURES | ||
Name | Relationship | Commercial Interest |
Brittany G. Craiglow, MD | Advisor | Dermavant, Eli Lilly, Pfizer, Regeneron, Sanofi-Genzyme |
Consultant | Eli Lilly, Pfizer | |
Speaker | Abbvie, Incyte, Eli Lilly, Pfizer, Regeneron, Sanofi-Genzyme | |
Brett King, MD, PhD |
| Advisory boards and/or is a consultant and/or is a clinical trial investigator and/or is on a Data Monitoring Committee for Abbvie, AltruBio Inc, Almirall, AnaptysBio, Arena Pharmaceuticals, Aslan Pharmaceuticals, Bioniz Therapeutics, Bristol Meyers Squibb, Concert Pharmaceuticals Inc, Equillium, Horizon Therapeutics, Eli Lilly and Company, Incyte Corp, Janssen Pharmaceuticals, LEO Pharma, Merck, Otsuka/Visterra Inc, Pfizer Inc, Q32 Bio Inc, Regeneron, Sanofi Genzyme, Sun Pharmaceutical, TWi Biotechnology Inc, Viela Bio, and Ventyx Biosciences Inc. He has served on speaker bureaus for Abbvie, Incyte, Eli Lilly, Pfizer, Regeneron and Sanofi Genzyme. He is a scientific advisor for BiologicsMD |
Dorothy Caputo, MA, BSN, RN, VP, Healthcare CE and Operations | N/A | Nothing to disclose |
Michele Bielarski, RN (planner/reviewer) | N/A | Nothing to disclose |
AKH Inc Staff and Planners | N/A | Nothing to disclose |
Tarsus dba LiVDerm Staff and Planners | N/A | Nothing to disclose |
All of the relevant financial relationships listed for these individuals have been mitigated. | ||
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
If you would like to opt out from future communications from AKH please send an email to optout@akhcme.com with your information with "Opt Out" in the subject line.
AKH Privacy Policy (link: https://akhcme.com/akhcme/pages/privacy
Available Credit
- 1.00 AAPA Category I CME
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC
- 1.00 Participation
Required Hardware/software
A computer with an internet connection
Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.